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Abstract
This study aimed to study the differences in Raman spectra of red blood cells (RBCs) among patients with b-thalassemia and controls
using laser tweezers Raman spectroscopy (LTRS) system.
A total of 33 patients with b-thalassemia major, 49 with b-thalassemia minor, and 65 controls were studied. Raman spectra of
RBCs for each sample were recorded. Principal component analysis (PCA), one-way analysis of variance (ANOVA), and
independent-sample t test were performed.
The intensities of Raman spectra of b-thalassemia (major and minor) RBCs were lower than those of controls, especially at bands
1546, 1603, and 1619cm–1. The intensity ratio of band 1546cm–1 to band 1448cm–1 demonstrated that there was a significant
difference between the spectra of b-thalassemia major (mostly below 2.15) and those of controls. The spectra of controls could be
well distinguished from those of b-thalassemia major using PCA. After normalization, the spectra of two different genotypes with b0/
b0 mutations mainly overlapped, while those with b+/b+ mutations had lower intensity at bands 1546, 1603, and 1619cm–1.
The present study provided Raman characteristics of RBCs in patients with b-thalassemia major and supported the use of LTRS
as a method for screening b-thalassemia major. The recognition rate for b-thalassemia minor needs to be further improved.
Abbreviations: HbA = adult hemoglobin, HbF = fetal hemoglobin, LTRS = laser tweezers Raman spectroscopy, MCH = mean
corpuscular hemoglobin, MCV = mean corpuscular volume, PCA = principal component analysis, RBCs = red blood cells.
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Thalassemia is an inherited blood disorder that may result in the
abnormal formation of hemoglobin and is mainly found in the
Mediterranean region, the Middle East, South China, and some
African countries.[1] b-thalassemia, as one of the most common
thalassemias, is prevalent in Southeast China.[2] It is the
consequence of impaired and reduced production of b-globin
chains, caused by point mutation in most cases. b-thalassemia isEditor: Ahmet Emre Eskazan.
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classified into two types depending on the severity of symptoms:
thalassemia major (also known as Cooley’s anemia) and
thalassemia intermedia. b-thalassemia major is characterized
by marked ineffective erythropoiesis and severe hemolysis.[3]
However, most of them rely on lifelong blood transfusions and
iron-chelating drugs for survival.[4,5]
Early identification and prevention can reduce the chances of
delivering babies with b-thalassemia. That is to say, performing
prenatal diagnosis on couples at a high risk of giving birth to a
baby with thalassemia major is the best choice while screening
b-thalassemia carriers. Recent screening methods for b-thalasse-
mia include complete blood count (typically showing anemia,
low mean corpuscular volume [MCV], microcytosis, and
hypochromia), cellulose acetate electrophoresis, high-perfor-
mance liquid chromatography, blood film observation (typically
showing target cells and polychromasia), and so on.[6] These tests
are more complicated, labor-intensive, and rigid for the
experimenters. Therefore, a rapid screening method is required.
With the development of laser technique, the combination of
laser trapping and Raman spectroscopy (laser tweezers Raman
spectroscopy [LTRS])[7,8] has been widely used in the research on
biological samples, including bacteria and blood cells, providing
extensive information on structure and molecular conformations
within the particles.[9–13] Because of differences in the hemoglo-
bin components of b-thalassemia and normal red blood cells
(RBCs), the quaternary structure of hemoglobin has changed,
making it possible for LTRS to differentiate between normal and
abnormal hemoglobin.[14–16] LTRS was used in the present study
for differentiating RBCs between controls and patients with
b-thalassemia, aiming to perform Raman characterization of
b-thalassemia and explore the possibility of LTRS as a potential
screening method for thalassemia.
Jia et al. Medicine (2018) 97:39 Medicine2. Materials and methods
2.1. Patients and materials
The study included 82 patients with b-thalassemia (33 major and
49 minor) and 65 controls who admitted to the First Affiliated
Hospital of Guangxi Medical University (Nanning, Guangxi
province, China). All subjects signed informed consent forms,
and the study was approved by the Ethics Committee of Guangxi
Medical University. All methods were performed in accordance
with the relevant guidelines and regulations.
Complete medical history and family history of each patient
were obtained. Then, the complete blood cell count with RBC
indices, blood smear, hemoglobin electrophoresis, and high-
performance liquid chromatography were performed. Patients
manifested with microcytosis (MCV<80 fL), hypochromia
(mean corpuscular hemoglobin (MCH)<27pg), hemoglobin
A2 (HbA2)≥3.5%, and fetal hemoglobin (HbF) 0.1% to 5%were
regarded as b-thalassemia minors. Patients manifested with
moderate-to-severe anemia HbF ≥40% were considered as
b-thalassemia majors. DNA analysis for b-globin mutations was
performed to confirm the selections.[17,18] The controls with
normal aforementioned tests were selected for continuous
collection of LTRS spectra of subjects, which consecutively
enrolled over the same period. For all subjects, infection, iron
deficiency anemia, leukemia, and a-thalassemia were excluded.
Of these 33 patients with b-thalassemia major, 10 received
blood transfusion at several weeks’ intervals, and the rest were
first diagnosed with no blood transfusion history. Patients with
b-thalassemia minor had some clinical manifestations.2.2. Preparation of RBCs
Blood (2mL) was taken by venipuncture from each patient with
b-thalassemia major when the patient was first diagnosed, or
before he/she received blood transfusions. All blood samples were
anti-coagulated using anticoagulant citrate dextrose solution
pipes. For preparing RBCs, every blood sample was centrifuged,
and the plasmawas discarded. The RBCswere washed twice with
0.9% saline solution and stored at 4°C. The RBCs of controls
were collected using the same method.2.3. Recording Raman spectra by LTRS
For every sample, 1mL aliquots of RBCs and 200mL of 0.9%
saline solution were placed in the LTRS system.[19] The RBCs
drifted at a speed of a few micrometers per second in saline
solution before they stuck to the bottom of the container. Once a
cell was captured by the laser tweezers, it was trapped within aTable 1
Baseline characteristics of patients with b-thalassemia and controls
b-thalassemia major (n=33)
Mean SD
Hemoglobin (g/L) 60.73 2.92
RBCs (1012/L) 2.83 0.16
MCV (fl) 69.47 1.04
MCH (pg) 22.06 0.46
MCHC, g/L 317.4 5.09
HbF (%) 79.19 3.88
HbA2 (%) 11.02 3.37
HbA2=hemoglobin A2, HbF= fetal hemoglobin, MCH=mean corpuscular hemoglobin, MCHC=mean co
cells, SD= standard deviation.
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small space and the Brownian motion was controlled. Then, the
Raman spectrum of this cell was recorded at the exposure time of
20 seconds using a 780.24nm laser. The power of the laser was
14.5 mW. For each sample, Raman spectra of 42 RBCs were
recorded.2.4. Statistical analysis
After subtracting background and smoothening, the average
spectra of 42 cells were obtained to represent the spectrum of
each sample. Origin (OriginLab Corp., Northampton, MA) and
SPSS (IBM, NY) software were used to process the Raman
spectroscopic data. The principal component analysis (PCA) was
performed for distinguishing spectra of RBCs from those of
patients with b-thalassemia and controls. In this analysis, a data
matrix consisting of 147 spectra (33 major, 49 minor, and 65
normal) in the bands 692 to 1834cm–1 was analyzed. Band 1448
cm–1 was chosen as the normalization point. Furthermore, the
intensity ratio of band 1546cm–1 to band 1448cm–1 was
investigated. No information about the disease statements of
patients was provided to the algorithm. Only the processed raw
data of spectra were used for this classification. A one-way
analysis of variance (ANOVA) was used to evaluate the
intensities of characteristic bands. A P value less than .05 was
statistically considered significant.3. Results
3.1. Hematological data
The hematological data are shown in Table 1. No age difference
was observed among the 3 groups. Also, no statistical difference
was found in the MCH concentration between b-thalassemia
major and b-thalassemia minor. Besides, no statistical difference
in RBCs was found between normal and b-thalassemia minor.
However, other parameters had statistically significant differ-
ences.3.2. Raman spectra of RBCs
Averaged Raman spectra of RBCs trapped in 0.9% saline
solution from the three groups are shown in Figure 1. The bands
of the Raman signal from the RBCs were assigned as described in
previous studies.[20,21]
Raman spectra showed the skeleton of hemoglobin in RBCs
(Fig. 1). Several prominent scattering bands were observed: 750
cm–1 resulting from the porphyrin breathing vibration mode, and
1000cm–1 resulting from the symmetric ring breathing mode of.
b-thalassemia minor (n=49) Control (n=65)
Mean SD Mean SD
103.66 2.02 139.24 2.50
5.07 0.11 4.64 0.08
64.17 0084 90.36 0.70
20.43 0.25 30.06 0.24
318.02 4.10 333.78 2.41
1.94 0.20 1.46 0.11
5.39 0.08 2.41 0.03
rpuscular hemoglobin concentration, MCV= erythrocyte mean corpuscular volume, RBCs= red blood
–1
Figure 1. Average spectra of b-thalassemia major, b-thalassemia minor, and normal RBCs (before normalization). RBCs= red blood cells.
Jia et al. Medicine (2018) 97:39 www.md-journal.comphenylalanine. The bands at 1448 and 1546cm originated from
bending vibrations of –CH2 and C–C (the amide II). Bands 1603
and 1619cm–1 stood for the C=C plane bending mode of
phenylalanine/tyrosine and the C=C stretchingmode of tyrosine/
tryptophan, respectively.[20] Before normalization (Fig. 1), the
normal spectral intensity was higher than those in other 2 groups,Figure 2. Intensities of wave number 1546cm–1 among the three group
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especially at bands 750, 1000, 1127, 1213, 1546, 1603, and
1619cm–1.
Control spectra were the highest at band 1546cm–1 compared
with the spectra forb-thalassemiaminorandmajor (Fig. 2) (P= .01).
Band 1448cm–1 was chosen as the normalization point. After
normalization, the spectra of b-thalassemia minor and controlss (one-way ANOVA, F=4.37, P= .01). ANOVA=analysis of variance.
Figure 3. Average spectra of b-thalassemia major, b-thalassemia minor, and normal RBCs (after normalization). RBCs= red blood cells.
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1213, 1546, 1603, and 1619cm–1 (Fig. 4A, C, and D) and
increased intensities at 890 to 945cm–1, 945 to 960cm–1, 1230 to
1240cm–1, 1240 to 1260cm–1, and 1260 to 1300cm–1 were
observed in patients with b-thalassemia major (Fig. 4B and C).
The intensity ratio with bands 1546 to 1448cm–1 (I1546/
I1448) was studied, suggesting a significant difference (P= .00)
between controls and b-thalassemia major (the ratio for majority
of patients with b-thalassemia major < 2.15; Fig.e 5). However,
no significant differences were found between b-thalassemia
minor and controls.
PCA was performed to gain further insight of these spectra
among the three groups. b-thalassemia major and normal RBCs
were displayed in a relatively independent space in a scatter plot
(Fig. 6). The same result was not confirmed for b-thalassemia
minor and controls.
Of the 33 cases with b-thalassemia major, 8 cases had
homozygous for codon 41–42M/41–42M (b0/b0) mutations, 5
cases had double heterozygous for codon 41–42M/17M (b0/b0)
mutations, and 2 cases had homozygous for codon -28M/-28M
(b+/b+). The results showed that the spectra of codon 41–42M/
41–42M (b0/b0) and 41–42M/17M (b0/b0) often overlapped
after normalization, while the spectra of codon -28M/28M
(b+/b+) showed lower intensity at bands 1546, 1603, and 1619
cm–1 (Fig. 7).
4. Discussion
b-thalassemia, one single-gene genetic disease, is a worldwide
health problem. Approximately 200 mutations or small
insertions/deletions interfere with the expression of b-globin,
resulting in the birth of a number of babies with b-thalassemia
every year.[22] Prevention focuses on screening the carriers.
Traditional screening methods include hemolysis, hemoglobin
solution, and electrophoresis based on the analysis of different4
compositions and quantity of hemoglobin. These complex and
labor-intensive methods may be burdensome for the countries
with a high prevalence of b-thalassemia.
Initially, the laser technologies for hemoglobin research needed
hemolysates. In 2003, Liu et al[23] compared infrared absorption
spectra and found decreased a-helix, increased tyrosine ring, and
cysteine Cys-SH in patients with b-thalassemia. These changes
could be detected using infrared spectroscopy andmight be useful
for screening b-thalassemia carriers. It was feasible to analyze the
composition at the cellular level with the development of laser
technology.[9,24–26] Using the technique of LTRS in a-thalassemia
research, Chen X et al[16] found that the RBCs of thalassemia
HbH-CS were easy to oxygenate, but difficult to deoxygenate,
providing a spectral vision on the oxygenation of thalassemia
HbH-CS. De Luca et al[27] found a decrease in the oxygenation
capability of b-thalassemic RBCs after comparing the Raman
spectra of six patients with b-thalassemia minor with controls.[27]
The Raman spectra of RBCs derived from patients with
b-thalassemia major in this study, using the LTRS system with
little labor intensity, revealed the characterization of hemoglobin
structure compared with those of age-matched non-thalassemic
individuals. The major Raman features included decreased
lactam II, increased number of b-sheets and b-turns, and change
in the proportion of globin chain (especially decreased intensity
ratio of band 1546cm–1 to band 1448cm–1). The possible
reasons for these results were greater differences in hemoglobin
composition in patients with b-thalassemia major (mainly HbF)
and normal individuals (mainly adult hemoglobin [HbA]), and
excessive deposition of alpha chain in thalassemic RBCs.
Different genotypes of b0/b0 mutations with b-thalassemia
major may have the same Raman characterization. Theoretically,
no differences were observed in the hemoglobin component
among these different genotypes of patients with b-thalassemia
major. Therefore, it is inferred that their Raman spectra are
similar to each other. However, spectra of b+/b+ mutations
having lower Raman intensity may possibly attribute to relatively
Figure 4. Specific bands area of b-thalassemia major, b-thalassemia minor, and normal RBCs. RBCs= red blood cells.
Figure 5. Intensity ratio with bands 1546 to 1448cm–1 (I1546/I1448) of normal RBCs, b-thalassemia minor, and b-thalassemia major. RBCs= red blood cells.
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Figure 6. Three-dimensional (3D) distribution of PCA results of b-thalassemiamajor and controls (A), and b-thalassemia minor and controls (B). Red triangle stands
for controls, blue cycle for b-thalassemia major, and green square for minor b-thalassemia. PCA=principal component analysis.
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This hypothesis was confirmed by the present study, although
further analysis with the increased number of samples is also
required to confirm this hypothesis.
Our results suggest that there is no significant spectra
difference between the b-thalassemia major and the normal
control. We considered that it is mainly attributable to the fact
that LTRS gave us a mixed spectrum of all hemoglobin
components in RBCs (i.e., HbA [a2b2], HbA2 [a2d2], and HbF
[a2g2]). The main hemoglobin components in normal andFigure 7. Raman spectra of different g
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b-thalassemia minor erythrocytes are HbA (> 90%), while
slightly elevated HbA2 and HbF are not recognized by current
spectral processing methods. For these reasons, our next work is
to isolate a single hemoglobin component (HbA, HbA2, and
HbF) by hemoglobin electrophoresis, to obtain their respective
Raman characterization, and to design a method for optimizing
the spectra data process.
b-thalassemia intermedia is a highly clinical concern with no
single method for identification.[17] In our future work, we will
attempt to apply LTRS system for identification of b-thalassemiaenotypes with b-thalassemia major.
Jia et al. Medicine (2018) 97:39 www.md-journal.comintermedia in the following aspects: the first one is the spectral
intensity. Our study has confirmed that the intensity of band
1546cm–1 is directly proportional to the hemoglobin level.
However, b-thalassemia intermedia (hemoglobin 7–9g/dl) and
b-thalassemia major (less than 6–7g/dl) all have different
hemoglobin levels. Therefore, it can be preliminarily differenti-
ated through the intensity of band 1546cm–1 whether that is a
b-thalassemia intermedia or b-thalassemia major. The second
aspect is related to the characteristics of HbA2. For b-thalassemia
major, the HbA2 level is lower than 4%. This may be helpful for
identification of b-thalassemia intermedia and b-thalassemia
major. The third aspect is I1546/I1448 which can reflect the
relative proportion of different hemoglobins. Though the HbF
level in b-thalassemia intermedia is not necessarily different to
that of b-thalassemia major, the relatively lower proportion of
HbF for most b-thalassemia intermedia individuals may be
reflected in I1546/I1448.
Although several methods were proposed before introducing
LTRS system to identify different kinds of thalassemia, however,
this technique has several advantages:(1) compared to classic testing (such as complete blood cell count
(CBC) index, blood smear and electrophoresis), it is reagent-
free, without any need for stain and fixatives;
compared with infrared absorption spectra, it is performed(2)
under physiological conditions, without any need for
hemolysates;
it uses only a low volume of RBCs, leaving blood material for(3)
other clinical purposes; and
it can be easily performed without rigid demands for(4)
expertise. Microfluidic devices are introduced with LTRS
for simplification, thereby reducing the cost and shortening
the time.
The is the first study on b-thalassemia major by using
LTRS system in mainland China. The present study provided
Raman characteristics of RBCs in patients with b-thalassemia
major and supported the use of LTRS as a method for screening
b-thalassemia major. However, the maneuverability of
LTRS for screening b-thalassemia minor requires further
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